Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as a powder for solution for injection for subcutaneous use. It is employed to treat infertility caused by anovulation and to facilitate controlled ovarian stimulation in assisted reproductive technology cycles.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product integrity and responsive technical support throughout the supply chain.

Menopur (menotrophin) is used in reproductive medicine to stimulate ovarian follicular development.

Infertility due to anovulation: promotes follicle growth to enable ovulation and increase the chance of conception. Controlled ovarian stimulation for assisted reproductive technology: enhances multiple follicle development to improve egg retrieval outcomes in IVF cycles. Ovulation induction for intrauterine insemination: supports follicular maturation to increase the likelihood of successful insemination.

Menopur may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Mild ovarian hyperstimulation syndrome: abdominal discomfort, bloating, and mild weight gain. - Headache: transient mild to moderate headache. - Nausea: occasional episodes of nausea.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, fluid accumulation, and risk of thrombosis. - Ovarian torsion: sudden severe pelvic pain requiring surgical intervention. - Allergic reaction: rash, urticaria, or anaphylaxis.

Before using Menopur, clinicians should consider several precautionary measures to ensure patient safety. - Patient selection: assess ovarian reserve and risk factors for ovarian hyperstimulation. - Monitoring: perform serial ultrasound and estradiol measurements during stimulation cycles. - Contraindications: avoid use in confirmed pregnancy, active hormone‑sensitive tumors, or uncontrolled thyroid disease. - Drug interactions: review concomitant estrogen‑containing therapies that may interfere with intended ovarian response. - Pregnancy: discontinue Menopur if pregnancy is confirmed and provide appropriate counseling. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect hormonal balance or ovarian response.

Major Interactions (Avoid): - Human chorionic gonadotropin (hCG): may exacerbate ovarian hyperstimulation when combined. - Estrogen therapy: can diminish the intended stimulatory effect of Menopur. - GnRH agonists used for down‑regulation: timing must be coordinated to prevent antagonistic effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may suppress endogenous gonadotropins and require careful scheduling. - Thyroid hormone replacement: stimulation may alter thyroid hormone requirements, necessitating monitoring.